ACE2-618-ABD-DDC

ACE2-618-ABD-DDC (also known as ACE2-618-DDC-ABD) is a bioengineered, soluble recombinant human angiotensin-converting enzyme 2 (ACE2) decoy protein. It consists of a shortened 618-amino-acid truncate of human ACE2 fused to an albumin-binding domain (ABD) to extend its in vivo half-life, and bridged via a dimerization motif hinge-like 4-cysteine dodecapeptide (DDC) to form a dimer with enhanced binding affinity for the SARS-CoV-2 spike protein. Developed by Northwestern University and its spinout Angiotensin Therapeutics, the decoy protein is designed to intercept SARS-CoV-2 variants (including Delta and Omicron) before they can bind to membrane-bound ACE2 receptors on host cells, thereby preventing viral entry. It is being investigated for the prevention and treatment of COVID-19 and associated organ injury (such as lung and kidney damage).

Other names

ACE2 1-618-ABD-DDCACE-2 1-618-ABD-DDCACE 2 1-618-ABD-DDCACE2 1-618-DDC-ABDACE-2 1-618-DDC-ABDACE 2 1-618-DDC-ABDACE2-1-618-ABD-DDCACE-2-1-618-ABD-DDCACE 2-1-618-ABD-DDCACE2-1-618-DDC-ABDACE-2-1-618-DDC-ABDACE 2-1-618-DDC-ABDsoluble ACE2 1-618-DDC-ABDsoluble ACE2-618-DDC-ABD